{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:38:30Z","timestamp":1792658310512,"version":"4.5.0"},"reference-count":39,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVES<\/jats:title>\n                    <jats:p>This ongoing phase 2\/3 interventional, open-label study evaluated nirmatrelvir\/ritonavir (NMV\/r) in pediatric participants with mild-to-moderate COVID-19 at risk for severe disease (due to underlying medical conditions). Primary objectives were pharmacokinetics (PK) and safety. We report data from participants aged at least 6\u00a0years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Twice daily (BID) oral NMV\/r was administered for 5\u00a0days to participants aged at least 6\u00a0years weighing at least 40\u00a0kg (Cohort 1) or 20 to &amp;lt;40\u00a0kg (Cohort 2). Day 1 and 5 sparse PK samples were incorporated into a previously developed population PK model to simulate exposure. Efficacy was extrapolated from adults by matching pediatric exposure to that in COVID-19-infected adults. Safety through Day 34 and supportive efficacy endpoints (hospitalization\/death, SARS-CoV-2 RNA concentration over time) were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Overall, 75 participants received at least 1 dose. Simulated exposure of NMV\/r 300\/100\u00a0mg BID for Cohort 1 and 150\/100\u00a0mg BID for Cohort 2 indicated more than 90% of participants achieved minimum NMV concentrations above the 90% effective concentration after dose 1 and at steady state. NMV\/r was safe and well tolerated. The most frequently reported adverse events (AEs) were diarrhea and headache (n\u2009=\u20093 [4%] participants each). No discontinuations because of treatment-related AEs occurred. No treatment-related serious AEs were reported. No COVID-19\u2212related hospitalizations or all-cause deaths were reported. Robust reductions in SARS-CoV-2 RNA from baseline to the end of treatment were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>In pediatric participants aged at least 6\u00a0years, NMV\/r 300\/100\u00a0mg BID (weighing \u226540\u00a0kg) and 150\/100\u00a0mg BID (weighing 20\u2013&amp;lt;40\u00a0kg) regimens achieved exposures similar to adults that were safe and had an antiviral effect.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1542\/peds.2025-073999","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:02:41Z","timestamp":1782345761000},"source":"Crossref","is-referenced-by-count":0,"title":["Nirmatrelvir\/Ritonavir for the Treatment of COVID-19 in Children Aged 6\u00a0Years and Older"],"prefix":"10.1542","volume":"158","author":[{"given":"Jacqueline","family":"Gerhart","sequence":"first","affiliation":[{"name":"1Pfizer Inc, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Leister-Tebbe","sequence":"additional","affiliation":[{"name":"1Pfizer Inc, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phylinda L. S.","family":"Chan","sequence":"additional","affiliation":[{"name":"2Pfizer R&D UK Ltd, Sandwich, Kent, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace A.","family":"McComsey","sequence":"additional","affiliation":[{"name":"3University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Carey","sequence":"additional","affiliation":[{"name":"4Pfizer Ltd, Walton Oaks, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihong","family":"Shi","sequence":"additional","affiliation":[{"name":"5Pfizer Inc, Groton, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Yan","sequence":"additional","affiliation":[{"name":"6Pfizer Inc, Sanford, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Leaney","sequence":"additional","affiliation":[{"name":"7Pfizer Ltd, Sandwich, Kent, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namita","family":"Singh","sequence":"additional","affiliation":[{"name":"8Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Lynn","family":"Baniecki","sequence":"additional","affiliation":[{"name":"9Pfizer Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunjie","family":"Guan","sequence":"additional","affiliation":[{"name":"9Pfizer Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Wisemandle","sequence":"additional","affiliation":[{"name":"10Pfizer Inc, Lake Forest, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi Shankar P.","family":"Singh","sequence":"additional","affiliation":[{"name":"9Pfizer Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hammond","sequence":"additional","affiliation":[{"name":"1Pfizer Inc, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"issue":"3","key":"2026102203465401100_r1","doi-asserted-by":"crossref","first-page":"e2023062570","DOI":"10.1542\/peds.2023-062570","article-title":"Postacute sequelae of SARS-CoV-2 in children","volume":"153","author":"Rao","year":"2024","journal-title":"Pediatrics."},{"key":"2026102203465401100_r2","article-title":"Children and COVID-19: state level data report","author":"American Academy of Pediatrics"},{"key":"2026102203465401100_r3","article-title":"Coronaviruses, including SARS-CoV-2 and MERS-CoV","author":"American Academy of Pediatrics"},{"key":"2026102203465401100_r4","article-title":"Information for pediatric healthcare providers","author":"Centers for Disease Control and Prevention"},{"issue":"6575","key":"2026102203465401100_r5","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2\u00a0Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science."},{"issue":"1","key":"2026102203465401100_r6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/cpt.2603","article-title":"Innovative randomized phase I study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of nirmatrelvir","volume":"112","author":"Singh","year":"2022","journal-title":"Clin Pharmacol Ther."},{"key":"2026102203465401100_r7","article-title":"FDA approves first oral antiviral for treatment of COVID-19 in adults","author":"US Food and Drug Administration"},{"key":"2026102203465401100_r8","volume-title":"Full Prescribing Information","year":"2025"},{"issue":"15","key":"2026102203465401100_r9","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med."},{"issue":"suppl_1","key":"2026102203465401100_r10","doi-asserted-by":"crossref","first-page":"ofae631.018","DOI":"10.1093\/ofid\/ofae631.018","article-title":"580. Pharmacokinetics (PK) and safety of nirmatrelvir\/ritonavir (NMV\/r) in non-hospitalized symptomatic pediatric patients ages 6\u00a0years and older with COVID-19 who are at increased risk of progression to severe disease (EPIC-Peds)","volume":"12","author":"Gerhart","year":"2025","journal-title":"Open Forum Infectious Diseases."},{"issue":"12","key":"2026102203465401100_r11","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/psp4.13039","article-title":"Dosing recommendation of nirmatrelvir\/ritonavir using an integrated population pharmacokinetic analysis","volume":"12","author":"Chan","year":"2023","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"key":"2026102203465401100_r12","volume-title":"Title 21\u2014Food and Drugs: Chapter 9, Federal Food, Drug, and Cosmetic Act, \u00a7355c","author":"U.S. Government Publishing Office","year":"2010"},{"issue":"3","key":"2026102203465401100_r13","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/cpt.1000","article-title":"Challenges and opportunities in the development of medical therapies for pediatric populations and the role of extrapolation","volume":"103","author":"Barrett","year":"2018","journal-title":"Clin Pharmacol Ther."},{"issue":"11","key":"2026102203465401100_r14","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/jcph.744","article-title":"Exposure matching for extrapolation of efficacy in pediatric drug development","volume":"56","author":"Mulugeta","year":"2016","journal-title":"J Clin Pharmacol."},{"issue":"2","key":"2026102203465401100_r15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40265-017-0850-x","article-title":"Evaluating safety reporting in paediatric antibiotic trials, 2000\u20132016: a systematic review and meta-analysis","volume":"78","author":"Pansa","year":"2018","journal-title":"Drugs."},{"issue":"5","key":"2026102203465401100_r16","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2165\/00003088-199733050-00001","article-title":"Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients","volume":"33","author":"Anderson","year":"1997","journal-title":"Clin Pharmacokinet."},{"issue":"6","key":"2026102203465401100_r17","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/152873901753215911","article-title":"Characterization of age-related changes in body weight and organ weights from birth to adolescence in humans","volume":"64","author":"Haddad","year":"2001","journal-title":"J Toxicol Environ Health A."},{"issue":"13","key":"2026102203465401100_r18","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2165\/00003088-200241130-00005","article-title":"Ontogeny of hepatic and renal systemic clearance pathways in infants: part II","volume":"41","author":"Alcorn","year":"2002","journal-title":"Clin Pharmacokinet."},{"issue":"13","key":"2026102203465401100_r19","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJMoa2309003","article-title":"Nirmatrelvir for vaccinated or unvaccinated adult outpatients with COVID-19","volume":"390","author":"Hammond","year":"2024","journal-title":"N Engl J Med."},{"key":"2026102203465401100_r20","article-title":"COVID-19 treatment information for providers and prescribers","author":"The Ottowa Hospital"},{"key":"2026102203465401100_r21","article-title":"Fact sheet for healthcare providers: emergency use authorization for Paxlovid\u2122","author":"US Food and Drug Administration"},{"key":"2026102203465401100_r22","article-title":"Australian guidelines for the clinical care of people with COVID-19","author":"National COVID-19 Clinical Evidence Taskforce"},{"key":"2026102203465401100_r23","article-title":"COVID-19 management in children","author":"Starship Child Health"},{"key":"2026102203465401100_r24","article-title":"Treatment guidelines for COVID-19","author":"National Centre for Infectious Diseases, Academy of Medicine Singapore, College of Physicians Singapore"},{"key":"2026102203465401100_r25","article-title":"Information leaflet for patients, parents and caregivers: Emergency Use Authorization (EUA) of Paxlovid\u2122 under regulation 29 for treatment of coronavirus disease 2019 (COVID-19)","author":"Pfizer Inc"},{"key":"2026102203465401100_r26","article-title":"Summary basis of decision - Paxlovid - Health Canada","author":"Government of Canada"},{"key":"2026102203465401100_r27","doi-asserted-by":"crossref","first-page":"935118","DOI":"10.3389\/fped.2022.935118","article-title":"Case report: Application of nirmatrelvir\/ritonavir to treat COVID-19 in a severe aplastic anemia child after allogeneic hematopoietic stem cell transplantation","volume":"10","author":"Huang","year":"2022","journal-title":"Front Pediatr."},{"issue":"25","key":"2026102203465401100_r28","doi-asserted-by":"crossref","first-page":"830","DOI":"10.15585\/mmwr.mm7125e2","article-title":"Hospitalization and emergency department encounters for COVID-19 after Paxlovid treatment - California, December 2021-May 2022","volume":"71","author":"Malden","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"11","key":"2026102203465401100_r29","doi-asserted-by":"crossref","first-page":"619","DOI":"10.21037\/atm-22-2791","article-title":"The feasibility, safety, and efficacy of Paxlovid treatment in SARS-CoV-2-infected children aged 6\u201314\u00a0years: a cohort study","volume":"10","author":"Yan","year":"2022","journal-title":"Ann Transl Med."},{"issue":"1","key":"2026102203465401100_r30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/INF.0000000000003740","article-title":"Monoclonal antibody and antiviral therapy for mild-to-moderate COVID-19 in pediatric patients","volume":"42","author":"Vora","year":"2023","journal-title":"Pediatr Infect Dis J."},{"issue":"8","key":"2026102203465401100_r31","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.21037\/tcr-24-70","article-title":"Effectiveness of Paxlovid in the treatment of the SARS-CoV-2 Omicron variant infection in children with hematologic malignancies: a retrospective cohort study","volume":"13","author":"Deng","year":"2024","journal-title":"Transl Cancer Res."},{"issue":"30","key":"2026102203465401100_r32","first-page":"e0207242231500","article-title":"Safety and efficacy of Paxlovid in pediatric intensive care unit patients with COVID-19","volume":"32","author":"Fan","journal-title":"Curr Med Chem."},{"issue":"3","key":"2026102203465401100_r33","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1097\/INF.0000000000004594","article-title":"Evolving COVID-19 landscape: assessing the effectiveness and safety profile of nirmatrelvir\/ritonavir in adolescents","volume":"44","author":"Lee","year":"2025","journal-title":"Pediatr Infect Dis J."},{"issue":"11","key":"2026102203465401100_r34","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.3855\/jidc.18685","article-title":"Application of nirmatrelvir\/ritonavir for the treatment of severe COVID-19 in a 3-year-old child","volume":"18","author":"Wang","year":"2024","journal-title":"J Infect Dev Ctries."},{"issue":"1","key":"2026102203465401100_r35","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1038\/s41467-024-49235-8","article-title":"Effectiveness of nirmatrelvir\/ritonavir in children and adolescents aged 12\u201317\u2009years following SARS-CoV-2 Omicron infection: a target trial emulation","volume":"15","author":"Wong","year":"2024","journal-title":"Nat Commun."},{"issue":"5","key":"2026102203465401100_r36","doi-asserted-by":"crossref","first-page":"e29662","DOI":"10.1002\/jmv.29662","article-title":"Clinical effectiveness of nirmatrelvir plus ritonavir on the short- and long-term outcome in high-risk children with COVID-19","volume":"96","author":"Wu","year":"2024","journal-title":"J Med Virol."},{"key":"2026102203465401100_r37","article-title":"People with certain medical conditions and COVID-19 risk factors","author":"Centers for Disease Control and Prevention (CDC)"},{"issue":"3","key":"2026102203465401100_r38","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/jpids\/piad116","article-title":"Guidance for prevention and management of COVID-19 in children and adolescents: a consensus statement from the Pediatric Infectious Diseases Society Pediatric COVID-19 Therapies Taskforce","volume":"13","author":"Willis","year":"2024","journal-title":"J Pediatric Infect Dis Soc."},{"key":"2026102203465401100_r39","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/bmj.p21","article-title":"What do we know about COVID-19 and children?","volume":"380","author":"Cox","year":"2023","journal-title":"BMJ."}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2025-073999\/1941218\/pediatrics.2025073999.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2025-073999\/1941218\/pediatrics.2025073999.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:47:01Z","timestamp":1792655221000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/158\/1\/e2025073999\/207906\/Nirmatrelvir-Ritonavir-for-the-Treatment-of-COVID"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,6,25]]},"published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2025-073999","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"article-number":"e2025073999"}}